Exogenous Ketone Supplementation in Females with Polycystic Ovary Syndrome

Launched by MCGILL UNIVERSITY · Dec 1, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether a special type of supplement called exogenous ketone monoester (KME) can help improve heart health in women who have polycystic ovary syndrome (PCOS). PCOS is a common condition affecting many women of reproductive age, and it can lead to serious heart health issues. The researchers want to see if taking KME can positively impact things like blood sugar control, blood pressure, and overall cardiovascular health in women with PCOS.

To participate in this study, women must be between the ages of 18 and 40 and have a confirmed diagnosis of PCOS. Participants will be asked to try two different drinks on separate days: one with the ketone supplement and one with a placebo (a drink with no active ingredients). Throughout the study, the researchers will measure various factors related to heart health to see how KME affects them compared to the placebo. It’s important to note that women who smoke, have certain health conditions, are pregnant, or take specific medications may not be eligible to join. This trial offers a chance to explore a new treatment that could potentially improve cardiovascular health for women with PCOS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All female participants will report female sex assigned at birth
• • All participants will be aged 18 to 40
• • PCOS diagnosis
• Exclusion Criteria:
• • Current smokers or a prolonged history of smoking
• • Presence or history of overt cardiometabolic disease (e.g., stage 2 hypertension, diabetes, heart disease), neurologic disease, or endocrinopathy (with the exception of PCOS)
• • Current pregnancy or currently breastfeeding
• • Current use of medications which may affect our outcomes of interest (e.g., anti-hypertensives, anti-androgens, metformin)